Stem cell and growth factor treatments for hair loss

Key takeaways

• This is a family of different products, not one treatment: your own fat-derived cells (stromal vascular fraction or cultured stem cells), cell-free secretions (conditioned medium or secretome), platelet products (PRP, PRF, growth factor concentrate), and recombinant growth factors in mesotherapy mixes. Exosomes have their own page (exosomes), as does PRP.
• Nothing in this family is approved for hair. The only FDA-approved stem cell products are blood-forming cells from umbilical cord blood for blood disorders, and the FDA lists stromal vascular fraction and exosomes among products marketed without approval (FDA consumer alert, 2020).
• Pooled conditioned-medium data say it works, but the randomized subset is modest. A meta-analysis of 8 trials (221 people) found density up 14.9 hairs per cm2 and thickness up 18.7 micrometres; in the 3 randomized trials the density gain shrank to 9.2 (Chien 2024).
• The most carefully blinded conditioned-medium trial found no difference from saline. In a 6-week split-scalp trial, both halves improved with all patients on 5% minoxidil, and minoxidil rather than the injection may have driven the gains (Legiawati 2023).
• A topical stem-cell extract beat vehicle in a small trial: twice-daily extract raised hair count 28.1% vs 7.1% at 16 weeks in 34 completers (Tak 2020).
• Adding stromal vascular fraction to PRP did not help in the one randomized trial that tested it (18 patients) (Behrangi 2024), though an earlier comparison found a larger density gain (51.6% vs 21.5%) (Butt 2020). The studies disagree.
• Growth factor concentrate looks promising but is poorly controlled. A 2026 meta-analysis of 12 studies (745 patients) reported gains of 57 hairs per cm2 at 12 months, but the trials had high bias risk and heterogeneity above 90% (Alali 2026). A second 2026 review could not conclude it beats PRP (Bansal 2026).

How it might work

Follicle stem cells respond to growth factors and Wnt signalling, and fat-derived cells secrete such factors, so the idea is to supply them through cells or their secretions. Animal data support a shift into the growth phase. Whether this reverses androgen-driven miniaturization in people is not established.

What the studies show

• Autologous SVF, 6 studies and 188 patients: improved density versus control or baseline with no severe adverse events, though fat harvesting is a surgical step (Kang 2022).
• Moneib 2025, 33 women: cultured autologous fat stem cells raised thickness and count at 12 and 24 weeks (Moneib 2025).
• Legiawati 2025, 60 people over 12 weeks: minoxidil, secretome, or both all improved, with the combination best (Legiawati 2025).
• Systematic review of 20 studies (724 patients) across conditioned media, platelet-rich fibrin, SVF, vesicles and stem cells: benefit in all categories, mild side effects, heterogeneous and short follow-up (Behrangi 2026).

How to read this: trials are tiny and short (6 to 24 weeks), use different products each time, often add minoxidil, and report percent change. Products in trials were made by the authors' labs; commercial clinic products are different and untested.

How it's used in studies

Protocols included a single SVF injection followed by PRP sessions, secretome injected at weeks 0, 4 and 8, and 2 mL of conditioned medium per side in one 6-week trial.

Side effects and safety

Risks include infection, scarring, granulomas and the dangers of unregulated products; fat harvesting has surgical risks, and donor-derived cell products add immune and contamination risks. A cosmetic serum with plant stem cell claims is not the product tested in these trials.

Bottom line

This is an investigational add-on that should come after proven options such as minoxidil and PRP-level treatments (see the treatment ladder). It does not regrow follicles that are gone. Ask any clinic about product source, whether cells are your own, and regulatory or ethics approval. Discuss with a doctor.